Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib Plus Rituximab in Untreated MCL
NCT06846489Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2025
- Primary completion
- Feb 2033
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL), sponsored by Sun Yat-sen University. Started Apr 2025; status: recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06846489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06846489.